Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Incyte Corp.

www.incyte.com

Latest From Incyte Corp.

Biopharma Quarterly Dealmaking Statistics, Q3 2017

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

BioPharmaceutical Deals

Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival endpoint regardless of PD-L1 expression, supporting a bid for expanded labeling.

ImmunoOncology Clinical Trials

Deals Shaping The Medical Industry, November 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.

Deals BioPharmaceutical

ACR Roundup: JAK Safety Shown Across Multiple Trials

Low cardiovascular risk was shown in trials presented at the ACR/ARHP annual meeting for Pfizer's, Lilly's and AbbVie's JAK inhibitors in rheumatoid arthritis; AbbVie's Phase II risankizumab results in PsA, biosimilar doubts and more from ACR.

Immune Disorders Inflammation
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Immune Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Incyte Pharmaceuticals Inc.
  • Incyte Genomics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Incyte Corp.
  • Senior Management
  • Hervé A Hoppenot, MD, Pres. & CEO
    David W Gryska, EVP, CFO
    Reid M Huber, PhD, EVP, CSO
    Vijay Iyengar, MD, EVP, Global Strategy & Corp. Dev.
    Steven H Stein, MD, EVP, CMO
  • Contact Info
  • Incyte Corp.
    Phone: (302) 498-6700
    1801 Augustine Cut-Off
    Wilmington, DE 19803
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register